94V Stock Overview
A clinical stage biotechnology company, develops aptamer-based pharmaceuticals for the treatment of acute life-threatening conditions.
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
Aptahem AB (publ) Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | SEK 0.28 |
| 52 Week High | SEK 0.36 |
| 52 Week Low | SEK 0.04 |
| Beta | -0.20 |
| 11 Month Change | 7.78% |
| 3 Month Change | 177.00% |
| 1 Year Change | n/a |
| 33 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | 97.86% |
Recent News & Updates
Recent updates
Shareholder Returns
| 94V | DE Biotechs | DE Market | |
|---|---|---|---|
| 7D | -13.7% | 2.2% | -1.9% |
| 1Y | n/a | -9.8% | 12.3% |
Return vs Industry: Insufficient data to determine how 94V performed against the German Biotechs industry.
Return vs Market: Insufficient data to determine how 94V performed against the German Market.
Price Volatility
| 94V volatility | |
|---|---|
| 94V Average Weekly Movement | 46.3% |
| Biotechs Industry Average Movement | 6.4% |
| Market Average Movement | 4.9% |
| 10% most volatile stocks in DE Market | 10.8% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: 94V's share price has been volatile over the past 3 months compared to the German market.
Volatility Over Time: Insufficient data to determine 94V's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2014 | 5 | Mikael Lindstam | www.aptahem.com |
Aptahem AB (publ), a clinical stage biotechnology company, develops aptamer-based pharmaceuticals for the treatment of acute life-threatening conditions. Its principal pharmaceutical candidate is Apta-1, which is in preclinical stage to prevent mortality rate caused by organ and tissue damage in sepsis patients. The company has collaborations with various academic groups, including Consortium with Orebro University, Seattle Children’s Research Institute, and University Health Network.
Aptahem AB (publ) Fundamentals Summary
| 94V fundamental statistics | |
|---|---|
| Market cap | €1.90m |
| Earnings (TTM) | -€986.14k |
| Revenue (TTM) | €232.47k |
8.2x
P/S Ratio-1.9x
P/E RatioIs 94V overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 94V income statement (TTM) | |
|---|---|
| Revenue | SEK 2.65m |
| Cost of Revenue | SEK 0 |
| Gross Profit | SEK 2.65m |
| Other Expenses | SEK 13.87m |
| Earnings | -SEK 11.22m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -1.98 |
| Gross Margin | 100.00% |
| Net Profit Margin | -424.20% |
| Debt/Equity Ratio | 0% |
How did 94V perform over the long term?
See historical performance and comparison